TriangleCD19.CAR T Cells (NCT03676504)
CD19.CAR T Cells trial for Acute Lymphoblastic Leukemia, Adult (NCT03676504). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
CAR T cells against CD19 are now standard for some relapsed leukemias and lymphomas. Most carry one of two co-stimulatory signals, and are made by companies at high doses.
The idea: give the cells both signals at once, make them in the hospital's own lab, and ask how few are enough.
At Heidelberg University Hospital, patients' T cells receive a third-generation receptor carrying CD28 and 4-1BB together, aiming for longer-lived cells. Doses were escalated across adults and children.
In thirteen adults with relapsed acute lymphoblastic leukemia, eight of ten evaluable reached complete remission with no neurotoxicity. In nine heavily pretreated CLL patients, six reached complete remission.
HD-CAR-1, led by Michael Schmitt, continues in Heidelberg, from age three. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.